Discovery and Validation of a Novel Biomarker for Cancer | Chapter 10 | Medical Science: Trends and Innovations Vol. 1

The identification and validation of novel biomarkers are critical for advancing cancer diagnosis, prognosis, and therapy. This chapter outlines the comprehensive process of discovering a novel biomarker for cancer, starting with an in-depth exploration of molecular data to identify potential candidates. We employed cutting-edge techniques such as subtraction hybridization, clinical and bioinformatics tools and statistical analyses to filter and validate Zinc Finger protein-like 1 (ZFPL1) as a biomarker candidate, resulting in the identification of a promising biomarker. Functional studies, both in vitro and in vivo, elucidated the biomarker’s role in cancer progression, revealing its involvement in key regulatory pathways. Clinical validation through patient cohort studies demonstrated the biomarker’s diagnostic accuracy and its potential for guiding personalized therapy. Our findings underscore the biomarker’s potential to improve clinical outcomes and pave the way for future research in this domain.

Discovery: In the discovery phase, we focused on identifying a novel biomarker for cancer by leveraging molecular approaches. The initial hypothesis was based on the differential expression of calcitonin-induced genes in cancerous vs. normal tissues. We employed subtraction hybridization using basal and calcitonin-induced prostate cancer cells, followed by rigorous characterization studies to pinpoint potential candidate(s). This process led to the identification of a promising biomarker, showing cancer-specific expression in the prostate. These findings suggest that the biomarker could play a crucial role in cancer diagnosis and treatment.

Identification of Function: Following the discovery, we investigated the potential function of ZFPL1 in prostate cancer cells by genetically modulating ZFPL1 expression in PC-3 cells, and then examining its impact on the changes in the rate of PC-3 cell proliferation, invasion and apoptosis. Initial results revealed that either the knock-down of ZFPL1 or its overexpression significantly altered the rate of PC-3 cell proliferation, invasion and apoptosis. Through a series of in vitro assays using cancer cell lines, we observed that the biomarker influenced the activation of the PI3K-Akt pathway, a central signaling pathway involved in tumor growth. In vivo studies in mouse models corroborated these findings, demonstrating reduced tumor growth upon biomarker inhibition. Mechanistic studies further elucidated the biomarker’s interaction with crucial molecular targets, indicating its potential as a therapeutic target. These results highlight the biomarker’s pivotal role in cancer biology and its promise for future therapeutic development.

Clinical Validation: The clinical validation phase involved a series of studies to assess the biomarker’s diagnostic and prognostic potential. We conducted a multi-center study with a diverse patient cohort of 508 men, ensuring robust and generalizable results. The biomarker demonstrated remarkably higher diagnostic accuracy than PSA, with a significant correlation between its expression levels and tumor progression. Further analysis revealed its potential to early diagnose patients for prostate cancer, particularly when either PSA or clinicopathological tests failed to diagnose. The ZFPL1 test can identify cancers at an early stage when they are more likely to be treatable. This early detection can significantly improve survival rates. ZFPL1 can be used to stratify patients into different risk categories, helping to determine who might need more intensive treatment or closer monitoring. These findings underscore the biomarker’s clinical relevance, offering a new tool for improving cancer diagnosis and treatment strategies, ultimately enhancing patient care.

 

Author (s) Details

 

Johnmesha Sanders
Department of Pharmacology, University of Louisiana College of Pharmacy, Monroe, LA 71009, USA.

 

Neshat Masud
Department of Pharmacology, University of Louisiana College of Pharmacy, Monroe, LA 71009, USA.

 

Kenneth Iczkowski
Pathology and Laboratory Medicine, University of California-Davis, USA.

 

Girish V. Shah
Department of Pharmacology, University of Louisiana College of Pharmacy, Monroe, LA 71009, USA.

 

Please see the book here:- https://doi.org/10.9734/bpi/msti/v1/3690